Baxter Qiaoguang Healthcare To Set Up Parenteral Nutrition Plant In Guangzhou
This article was originally published in PharmAsia News
Baxter Qiaoguang Healthcare (Guangzhou), a 50-50 joint venture between Guangzhou Baiyunshan Pharmaceutical and Baxter, has announced that it will invest more than 300 million yuan (43.46 million) to set up new facilities to produce world-class parenteral nutrition products in Guangzhou Economic and Technological Development Zone. The new plant will start operating by the end of 2010, with an annual output and value of 20 million packs and $200 million, respectively. Baxter China notes that China is the world's fourth biggest parenteral nutrition market at $233 million and growing at 10 percent year on year; it will be one of the company's three most important markets globally. (Click here for more - Chinese Language)
You may also be interested in...
Guardant’s CEO anticipates accelerated adoption and reimbursement of its FDA-approved liquid biopsy assay and more biopharma partnerships.
Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m.
Agency commissioner appeals to AMA audience to communicate message that FDA review decisions are based on good science.